Lisata Therapeutics (LSTA) news
Recent news
Lisata Therapeutics - Board expanded from seven to eight members with newly created seat
Lisata Therapeutics, Inc. (Nasdaq: LSTA) has expanded its board of directors from seven to eight members with the creation of a new seat, according to the company’s corporate governance information . The addition brings the total number of board members to eight, with the new appointee expected to…
AInvest Wire · 12h agoLisata Therapeutics appoints Jeff Farrow to board of directors
AInvest Wire · 12h agoLisata Therapeutics announces new method of use patent granted for Certepetide in the treatment of pancreatic cancer and other solid tumors
AInvest Wire · 6d agoLisata Therapeutics, - To use net proceeds to advance Mar001/005 and Mar002 with topline phase 2 data expected Q4 2027
Lisata Therapeutics is utilizing net proceeds from recent financing to advance its pipeline of investigational therapies, including MAR001 and MAR002. The company is preparing for key clinical milestones, with topline data from Phase 2 trials expected in the fourth quarter of 2027. MAR001 is…
AInvest Wire · Sep 17, 2026Lisata Therapeutics: Investors to receive 150,867.995 Series C preferred shares at $1,491.37 per share
Lisata Therapeutics, Inc. has announced that investors will receive 150,867.995 Series C preferred shares at a price of $1,491.37 per share. This offering is part of the company’s ongoing capital-raising efforts and is intended to support its operations and development initiatives. The transaction…
AInvest Wire · Sep 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.